English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, November 20, 2019
Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
エーザイ、パーキンソン病治療剤「エクフィナ(R)錠 50mg」(一般名:サフィナミドメシル酸塩)を日本において新発売
Wednesday, November 13, 2019
エーザイ、人事異動を発表
Tuesday, November 5, 2019
エーザイ、EZH2阻害剤タゼメトスタットについて日本以外の地域における売上ロイヤルティ受領の権利をRoyalty Pharmaに譲渡
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Wednesday, October 23, 2019
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
バイオジェンとエーザイ、アデュカヌマブ 臨床第III相試験で得られた大規模データセットの新たな解析結果に基づき、アルツハイマー病を対象とした新薬承認申請を予定
Wednesday, October 16, 2019
エーザイ、抗てんかん剤「フィコンパ(R)」部分てんかん併用療法に係る適応で中国当局より新薬承認を取得
Tuesday, October 15, 2019
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Tuesday, October 1, 2019
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575